Capability
Radiopharmaceuticals end to end
Pre-clinical to commercial, isotope strategy to dose handling. Bracken has worked across the radiopharma value chain in ways few firms can claim.
Meet The Bracken Group
Twenty minutes with Bracken at SNMMI 2026.
Whether you're scoping a radiopharmaceutical program, designing imaging endpoints into a trial, or sorting out regulatory and commercial strategy, Bracken is the deep, neutral expert across the value chain.
Colin G. Miller, PhD, FIPEM, CSci, FICR
Co-founder and CEO of The Bracken Group. Author of three books and more than 70 peer-reviewed articles. Thirty plus years in medical imaging in clinical trials. Recognized leader in nuclear cardiology, oncology imaging, and theranostics.
Bio paragraph to be expanded with Bracken's preferred framing for the SNMMI audience.
Three things we're known for.
Capability
Imaging & endpoints in clinical trials
Bracken's signature work: medical imaging as a regulated endpoint. Protocol design, central reading, dosimetry, and the operational realities of running it.
Capability
Regulatory & commercial strategy
From IND through label to launch readiness. We help radiopharma teams sequence the regulatory and commercial work without losing the science.
Partnership in motion
Bracken × LabConnect: expanding radiopharmaceutical support.
Bracken's recent partnership with LabConnect expands the operational reach of radiopharmaceutical clinical trials, pairing Bracken's imaging and regulatory expertise with LabConnect's central-lab footprint.
Specific scope and joint capabilities to be finalized for SNMMI 2026 messaging.
LabConnect at SNMMI 2026: Booth #2535. Stop by both us and them on the floor.
Book 20 minutes
Talk to Bracken at SNMMI 2026.
On-site at the Los Angeles Convention Center, May 30 to June 2. Pick a time that works and we'll find you on the floor.
Calendly embed goes here at launch.
Drop the booking-link iframe into BookEmbed.tsx when the Calendly URL is ready.